First analysis of 10-year trends in national factor concentrates usage in haemophilia: Data from CHARMS, the Canadian hemophilia assessment and resource management system

Haemophilia

Volumn 20, Issue 4, 2014, Pages

  Traore, A N ^a   Chan, A K C ^b   Webert, K E ^b   Heddle, N ^b   Ritchie, B ^c   St Louis, J ^d   Teitel, J ^e   Lillicrap, D ^f   Iorio, A ^b   Walker, I ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f QUEEN S UNIVERSITY   (Canada)

Author keywords

Canada; Coagulation factor concentrate; Haemophilia; Home infusion; Prophylaxis

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; CANADA; CANADIAN HEMOPHILIA ASSESSMENT AND RESOURCE MANAGEMENT SYSTEM; COMPUTER PROGRAM; CORRELATION ANALYSIS; DATA BASE; FEMALE; HEALTH CARE SURVEY; HEALTH CARE UTILIZATION; HEMOPHILIA A; HEMOPHILIA B; HOME CARE; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT INDICATION; HEALTH CARE PLANNING; TRENDS; UTILIZATION;

BLOOD COAGULATION FACTORS; CANADA; FEMALE; HEALTH RESOURCES; HEMOPHILIA A; HUMANS; MALE;

EID: 84904600959     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12477     Document Type: Article

References (43)

1. Kaushansky K, Lichtman M, Beutler E, Kipps T, Prchal J, Seligsohn U. Williams Hematology. 8th ed. New York: McGraw-Hill, 2010.
2. Soucie JM, Nuss R, Evatt B et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 2000; 96: 437-42.
3. Smith PS, Levine PH. The benefits of comprehensive care of hemophilia: a five-year study of outcomes. Am J Public Health 1984; 74: 616-7.
4. Hoots WK. Comprehensive care for hemophilia and related inherited bleeding disorders: why it matters. Curr Hematol Rep 2003; 2: 395-401.
5. Soucie JM, Symons J, Evatt B, Brettler D, Huszti H, Linden J. Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. Haemophilia 2001; 7: 198-206.
6. Hay CR. The UK Haemophilia Database: a tool for reasearch, audit and healthcare planning. Haemophilia 2004; 10: 21.
7. Kar A, Potnis-Lele M. Haemophilia data collection in developing countries: example of the haemophilia database of Maharashtra. Haemophilia 2004; 10: 301-4.
8. Walker I. The Canadian Hemophilia Registry. Haemophilia 2004; 10: 21-2.
9. Petrini P. Identifying and overcoming barriers to prophylaxis in the management of haemophilia. Haemophilia 2007; 13: 16-22.
10. Manco-Johnson M. Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice. Haemophilia 2007; 13: 4-9.
11. Oldenburg J. Prophylaxis in bleeding disorders. Thromb Res 2011; 127: S14-7.
12. Carcao M, Lambert T. Prophylaxis in haemophilia with inhibitors: update from international experience. Haemophilia 2010; 16: 16-23.
13. Ettingshausen CE, Kreuz W. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: a prospective clinical case series. Haemophilia 2010; 16: 90-100.
14. Den Uijl I, Mauser-Bunschoten EP, Roosendaal G, Schutgens R, Fischer K. Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment. Haemophilia 2009; 15: 1215-8.
15. Valentino LA, Carcao M, Mathew P et al. The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report. Haemophilia 2009; 15: 959-65.
16. Berntorp E. Prophylaxis in von Willebrand disease. Haemophilia 2008; 14: 47-53.
17. Biss TT, Chan AK, Blanchette VS, Iwenofu LN, Mclimont M, Carcao MD. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia 2008; 14: 923-30.
18. Schlammadinger A, Ilonczai P, Olah Z, Razso K, Boda Z. Low dose factor concentrate prophylaxis in patients with severe haemorrhagic disorders. Blood Rev 2007; 21: S102-S.
19. Walker IR, Sek JT, Almonte TM et al. Developing a tracking system for coagulation factor concentrates in southern Ontario. Transfusion 2003; 43: 556-62.
20. Manco-Johnson MJ, Riske B, Kasper CK. Advances in care of children with hemophilia. Semin Thromb Hemost 2003; 29: 585-94.
21. Rosendaal FR, Smit C, Briet E. Hemophilia Treatment in Historical-Perspective - A Review of Medical and Social Developments. Ann Hematol 1991; 62: 5-15.
22. Colvin BT, Astermark J, Fischer K et al. European principles of haemophilia care. Haemophilia 2008; 14: 361-74.
23. Walker I, Pai M, Akabutu J et al. The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates. Transfusion 1995; 35: 548-51.
24. Iorio A, Oliovecchio E, Morfini M, Mannucci PM. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. Haemophilia 2008; 14: 444-53.
25. Walker I. Survey of the Canadian hemophilia population. Can J Public Health 1991; 82: 13.
26. Association of Hemophilia Clinic Directors of Canada. Effect of using safer blood products on prevalence of HIV infection in haemophilic Canadians. BMJ 1993; 306: 2.
27. Krever Commission. Commission of Inquiry on the Blood System in Canada. 1997. Available at http://epe.lac-bac.gc.ca/100/200/301/hcan-scan/commission_blood_final_rep-e/index.html.Accessed 11 June 2014.
28. Arnold DM, Webert KE, Carruthers J et al. Trends in the utilization and wastage of coagulation factor concentrates: the application of a regional tracking programme. Haemophilia 2007; 13: 271-8.
29. Walker I, Sigouin C, Sek J et al. Comparing hand-held computers and paper diaries for haemophilia home therapy: a randomized trial. Haemophilia 2004; 10: 698-704.
30. World Federation of Hemophilia. Guidelines for the Management of Hemophilia. World Federation of Hemophilia. 2005. Available at http://www1.wfh.org/publications/files/pdf-1472.pdf. Accessed 11 June 2014.
31. Brackmann HH, Eickhoff HJ, Oldenburg J, Hammerstein U. Long-term therapy and on-demand treatment of children and adolescents with severe haemophilia A: 12 years of experience. Haemostasis 1992; 22: 9.
32. World Health organization. Report of joint WHO/WFH Meeting on the Control of Haemophilia: Delivery of Treatment for Haemophilia. 2002. Available at http://www1.wfh.org/publication/files/pdf-1451.pdf. Accessed 11 June 2014.
33. van den Berg HM, Fischer K, Mauser-Bunschoten EP et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-5.
34. Lillicrap D. Improvements in factor concentrates. Curr Opin Hematol 2010; 17: 393-7.
35. Blanchette P, Rivard G, Israels S et al. A survey of factor prophylaxis in the Canadian haemophilia A population. Haemophilia 2004; 10: 679-83.
36. Blanchette VS, McCready M, Achonu C, Abdolell M, Rivard G, Manco-Johnson MJ. A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia 2003; 9: 19-26.
37. Blanchette VS. Prophylaxis in the haemophilia population. Haemophilia 2010; 16(Suppl 5): 181-8; 2.
38. Valentino LA. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors. Haemophilia 2010; 16: 263-71.
39. Luu H, Ewenstein B. FEIBA (R) safety profile in multiple modes of clinical and home-therapy application. Haemophilia 2004; 10: 10-6.
40. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA((R))) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia 2007; 13: 249-55.
41. Dimichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13(Suppl 1): 1-22.
42. Arnold DM, Julian JA, Walker IR. Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up. Blood 2006; 108: 460-4.
43. Walker IR, Julian JA. Causes of death in Canadians with haemophilia 1980-1995. Association of Hemophilia Clinic Directors of Canada. Haemophilia 1998; 4: 714-20.